Don’t see what you’re looking for? Use the search box on MDA’s Quest magazine.
Posted on Wednesday, May 1, 2013 - 09:23, By: Amy Madsen
Update (Aug. 26, 2013): This trial is recruiting participants at its Boston, Mass., trial site.
ALS TDI’s phase 2a clinical trial will assess the safety and tolerability of an approved multiple sclerosis drug, Gilenya, in people with amyotrophic lateral sclerosis
Posted on Monday, February 11, 2013 - 06:12, By: Amy Madsen
Update (Aug. 26, 2013): This trial is recruiting participants at its Boston trial site. For updates about the trial’s other sites, see Gilenya in Amyotrophic Lateral Sclerosis, or search for trial ID NCT01786174 at ClinicalTrials.gov.